Compounds, compositions and methods thereof
Novel STING inhibitors, represented by compounds of formula I, I-a, and I-b, address the limitations of existing STING inhibitors by offering high potency and selectivity, effectively treating autoimmune and inflammatory diseases through targeted STING pathway modulation.
WO2026114276A1PCT designated stage Publication Date: 2026-06-04JIANGSU JITRI MOLECULAR ENG INST CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- JIANGSU JITRI MOLECULAR ENG INST CO LTD
- Filing Date
- 2025-11-26
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Current STING inhibitors, such as H-151 and SN-011, are metabolically unstable, have poor water solubility, and lack selectivity, posing challenges in treating autoimmune and autoinflammatory diseases associated with abnormal STING activation.
Method used
Development of novel compounds, such as those of formula I, I-a, and I-b, or their salts, which act as potent and selective STING inhibitors, modulating STING pathway activity to reduce activation and associated cytokine release.
Benefits of technology
The compounds provide high potency and low toxicity, effectively inhibiting STING activation, reducing TBK1 activity, and alleviating conditions like systemic lupus erythematosus, Crohn's disease, and various inflammatory and autoimmune disorders.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2025137871-FTAPPB-I100001 
Figure PCTCN2025137871-FTAPPB-I100002 
Figure PCTCN2025137871-FTAPPB-I100003
Abstract
Among other things, the present disclosure provides compounds of formula I or salts thereof. In some embodiments, provided compounds are useful as STING inhibitors. In some embodiments, the present disclosure provides methods for preventing or treating STING-associated conditions, diseases or disorders.
Need to check novelty before this filing date? Find Prior Art